Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11434090 | 0.88 | XDH (0.43) | XDHSLC22A12KDM4CMAP2K1NOTUM | |
| SCHEMBL2435113 | 0.86 | CYP2A6 (0.40) | XDHSLC22A12KDM4CMAP2K1CYP2A6 | |
| SCHEMBL23480907 | 0.86 | SLC22A12 (0.46) | XDHSLC22A12KDM4CMAP2K1NOTUM | |
| SCHEMBL29740345 | 0.84 | CYP2A6 (0.41) | XDHSLC22A12KDM4CMAP2K1CYP2A6 | |
| SCHEMBL31084678 | 0.84 | XDH (0.45) | XDHSLC22A12KDM4CMAP2K1NOTUM | |
| SCHEMBL1169569 | 0.84 | CYP2A6 (0.41) | XDHSLC22A12KDM4CMAP2K1CYP2A6 | |
| SCHEMBL30400690 | 0.83 | PPARA (0.50) | — | |
| SCHEMBL6132151 | 0.82 | GABRP (0.41) | KDM4CGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10412862 | 0.82 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL286231 | 0.81 | CYP2A6 (0.43) | MAP2K1CYP2A6MRGPRX4SETDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656373-B | Cyano-substituted benzamide compound and application thereof | 南通泰禾化工股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-118005638-A | Pyrazolo [3,4-d ] pyrimidine structure-containing compound, and preparation method and application thereof | 西安新通药物研究股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| EP-4093400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | The Trustees of Princeton University (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022135447-A1 | CYANO-SUBSTITUTED BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南通泰禾化工股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135447-A1 | CYANO-SUBSTITUTED BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南通泰禾化工股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-114656373-A | Cyano-substituted benzamide compound and application thereof | 南通泰禾化工股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2021151062-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERISTY (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-3442958-B1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-8101778-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319627-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
| WO-2011084519-A1 | METHODS OF SYNTHESIZING FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| CN-101414121-A | Radiation sensitive composition for forming a colored layer, color filter and color liquid crystal display device | JSR CORP (JP) | 2009-04-22 | — | — | CN | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1773786-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005123050-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | XDH 156/4885SLC22A12 4471/4885KDM4C 1128/4885 |
| US-20110319627-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | F12, F9, F7 | XDH 39/4885SLC22A12 2713/4885KDM4C 1071/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | XDH 292/4885SLC22A12 1576/4885KDM4C 1712/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | XDH 156/4885SLC22A12 4471/4885KDM4C 1128/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | XDH 245/4885SLC22A12 3938/4885KDM4C 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.